Sumitomo Pharma Statistics
Total Valuation
Sumitomo Pharma has a market cap or net worth of 1.43 billion. The enterprise value is 3.29 billion.
| Market Cap | 1.43B |
| Enterprise Value | 3.29B |
Important Dates
The next estimated earnings date is Friday, January 31, 2025.
| Earnings Date | Jan 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 180.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.68 |
| EV / Sales | 1.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.41 |
Financial Position
The company has a current ratio of 0.64, with a Debt / Equity ratio of 3.41.
| Current Ratio | 0.64 |
| Quick Ratio | 0.35 |
| Debt / Equity | 3.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | -5.30 |
| Interest Coverage | -4.97 |
Financial Efficiency
Return on equity (ROE) is -106.19% and return on invested capital (ROIC) is -26.63%.
| Return on Equity (ROE) | -106.19% |
| Return on Assets (ROA) | -17.76% |
| Return on Capital (ROIC) | -26.63% |
| Revenue Per Employee | 480,290 |
| Profits Per Employee | -391,696 |
| Employee Count | 4,980 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 1.30 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.59% in the last 52 weeks. The beta is 0.54, so Sumitomo Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +20.59% |
| 50-Day Moving Average | 3.41 |
| 200-Day Moving Average | 11.30 |
| Relative Strength Index (RSI) | 56.35 |
| Average Volume (20 Days) | 5,348 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sumitomo Pharma had revenue of 2.39 billion and -1.95 billion in losses. Loss per share was -4.91.
| Revenue | 2.39B |
| Gross Profit | 1.42B |
| Operating Income | -1.93B |
| Pretax Income | -2.09B |
| Net Income | -1.95B |
| EBITDA | -1.70B |
| EBIT | -1.93B |
| Loss Per Share | -4.91 |
Balance Sheet
The company has 691.60 million in cash and 2.72 billion in debt, giving a net cash position of -2.03 billion.
| Cash & Cash Equivalents | 691.60M |
| Total Debt | 2.72B |
| Net Cash | -2.03B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 797.44M |
| Book Value Per Share | 2.01 |
| Working Capital | -1.20B |
Cash Flow
In the last 12 months, operating cash flow was -438.66 million and capital expenditures -73.86 million, giving a free cash flow of -512.52 million.
| Operating Cash Flow | -438.66M |
| Capital Expenditures | -73.86M |
| Free Cash Flow | -512.52M |
| FCF Per Share | n/a |
Margins
Gross margin is 59.56%, with operating and profit margins of -80.78% and -81.55%.
| Gross Margin | 59.56% |
| Operating Margin | -80.78% |
| Pretax Margin | -87.37% |
| Profit Margin | -81.55% |
| EBITDA Margin | -71.21% |
| EBIT Margin | -80.78% |
| FCF Margin | n/a |
Dividends & Yields
Sumitomo Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.00% |
| Shareholder Yield | 0.00% |
| Earnings Yield | -136.28% |
| FCF Yield | -35.81% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sumitomo Pharma has an Altman Z-Score of -0.84. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.84 |
| Piotroski F-Score | n/a |